The Mevalonate Synthesis Pathway as a Therapeutic Target in Cancer

Clinical Orthopaedics and Related Research

Volumn 415, Issue SUPPL., 2003, Pages

  Andela, Valentine B ^a   Pirri, Michael ^a   Schwarz, Edward M ^a   Puzas, Edward J ^a   O'Keefe, Regis J ^a   Rosenblatt, Joseph D ^b   Rosier, Randy N ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; COMPACTIN; ENZYME INHIBITOR; FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; GERANYLGERANYLTRANSFERASE INHIBITOR; GERANYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; MEVALONIC ACID; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PYROPHOSPHATE; RHO FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER THERAPY; CELL ADHESION; CELL INVASION; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; MEVALONATE SYNTHESIS; NONHUMAN; PRIORITY JOURNAL; SUPPLEMENTATION; SYNTHESIS; THERAPEUTIC TARGET;

EID: 0142219301     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/01.blo.0000093846.72468.66     Document Type: Conference Paper

References (32)

1. Adami S, Braga V, Guidi G, et al: Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J Bone Miner Res 15:599-604, 2000.
2. rho proteins. J Biol Chem 267:20033-20038, 1992.
3. Andela VB: Synergism of aminobisphosphonates and farnesyl transferase inhibitors on tumor metastasis. Clin Orthop 397:228-239, 2002.
4. Aspenstrom P: The Rho GTPases have multiple effects on the actin cytoskeleton. Exp Cell Res 246: 20-25, 1999.
5. Assoian RK, Zhu X: Cell anchorage and the cytoskeleton as partners in growth factor dependent cell cycle progression. Curr Opin Cell Biol 9:93-98, 1997.
6. Benford HL, Frith JC, Auriola S, Mönkkönen J, Rogers MJ: Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 56:131-140, 1999.
7. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G: Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 373:231-241, 2000.
8. Boissier S, Magnetto S, Frappart L, et al: Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 57:3890-3894, 1997.
9. Casey PJ: Biochemistry of protein prenylation. J Lipid Res 33:1731-1740, 1992.
10. Chan KKW, Oza AM, Siu LL: The statins as anticancer agents. Clin Cancer Res 9:10-19, 2003.
11. Coxon FP, Helfrich MH, Van't Hof R, et al: Protein geranylgeranylation is required for osteoclast formation, function and survival. J Bone Miner Res 15: 1467-1476, 2000.
12. del Peso L, Hernandez-Alcoceba R, Embade N, et al: Rho proteins induce metatstatic properties in vivo. Oncogene 15:3047-3057, 1997.
13. Diel IJ, Solomayer EF, Bastert G: Bisphosphonates and the prevention of metastasis: First evidences from pre-clinical and clinical studies. Cancer 88: 3080-3088, 2000.
14. Edwards CJ, Russell RG, Spector TD: Statins and bone: Myth or reality. Calcif Tissue Int 69:63-66, 2001.
15. Fisher JE, Rogers MJ, Halasy JM, et al: Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation invitro. Proc Natl Acad Sci USA 96:133-138, 1999.
16. Gelb MH, Scholten JD, Sebolt-Leopold JS: Protein prenylation: from discovery to prospects for cancer treatment. Curr Opin Chem Biol 2:40-48, 1998.
17. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 343:425-430, 1990.
18. Hall A: Rho GTPases and the actin cytoskeleton. Science 279:509-514, 1998.
19. Hall TJ, Chambers TJ: Molecular aspects of osteoclast function. Inflamm Res 45:1-9, 1999.
20. Luckman SP, Hughes DE, Coxon FP, et al: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581-589, 1998.
21. Michaelson D, Silletti J, Murphy G, et al: Differential localization of RhoGTPases in live cells: Regulation by hypervariable regions and RhoGDI binding. J Cell Biol 152:111-126, 2001.
22. Park HJ, Kong D, Iruela-Arispe L, et al: 3-HMG coA reductase inhibitors intefere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 91:143-150, 2002.
23. Prendergast GC, Davide JP, deSolms SJ, et al: Farnesyl transferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol 14:4193-4202, 1994.
24. Sasaki A, Boyce BF, Story B, et al: Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55:3551-3557, 1995.
25. Shipman CM, Croucher PI, Russell RG, Helfrich MH, Rogers MJ: The bisphosphonate icandronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 58:5294-5297, 1998.
26. Symons M: The Rac and Rho pathways as a source of drug targets for Ras mediated malignancies. Curr Opin Biotechnol 6:668-674, 1995.
27. Van Beek E, Lowik C, van der Pluijm G, Papapoulos S: Role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro. J Bone Miner Res 5: 722-729, 1999.
28. Van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S: Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 255:491-494, 1999.
29. Van Golen KL, Bao L, DiVito MM, et al: Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol Cancer Ther 1:575-583, 2002.
30. Virtanen SS, Väänänen PL, Härkönen, Lakkakorpi PT:Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 62:2708-2714, 2002.
31. Wong WW, Dimitroulakos J, Minden MD, Penn LZ: HMG-CoA reductase inhibitors and the malignant cell: The statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16:508-519, 2002.
32. Zhang FL, Casey PJ: Protein prenylation: Molecular mechanism and functional consequences. Annu Rev Biochem 65:241-269, 1996.